Radiotherapy Dose Optimization via Clinical Knowledge Based Reinforcement Learning

 $\begin{array}{c} \text{Paul Dubois}^{1,2[0009-0003-3856-8048]}, \\ \text{Paul-Henry Cournède}^{1[0000-0001-7679-6197]}, \text{ and} \\ \text{Nikos Paragios}^{2[0000-0002-9668-4763]} \end{array}$

Biomathematics, MICS, CentraleSupélec, Université Paris-Saclay {p.dubois,paul-henry.cournede}@centralesupelec.fr https://biomathematics.mics.centralesupelec.fr/

TheraPanacea, Paris, France {p.dubois,n.paragios}@therapanacea.eu https://www.therapanacea.eu/

Abstract. A radiation therapy plan finds an equilibrium between goals with no universal prioritization. The delicate balance between multiple objectives is typically done manually. The optimization process is further hindered by complex mathematical aspects, involving non-convex multi-objective inverse problems with a vast solution space. Expert bias introduces variability in clinical practice, as the preferences of radiation oncologists and medical physicists shape treatment planning.

To surmount these challenges, we propose a first step towards a fully automated approach, using an innovative deep-learning framework. Using a clinically meaningful distance between doses, we trained a reinforcement learning agent to mimic a set of plans. This method allows automatic navigation toward acceptable solutions via the exploitation of optimal dose distributions found by human planners on previously treated patients. As this is ongoing research, we generated synthetic phantom patients and associated realistic clinical doses. Our deep learning agent successfully learned correct actions leading to treatment plans similar to past cases ones. The incapacity to reproduce human-like dose plans hinders adopting a fully automated treatment planning system; this method could start paving the way towards human-less treatment planning system technologies. In future work, we hope to be able to apply this technique to real cases.

Keywords: Radiotherapy \cdot Dose Optimization \cdot Reinforcement Learning \cdot Deep Learning.

1 Introduction

In contemporary radiation therapy, photon intensity modulated radiation therapy (IMRT) is a pivotal technique to attain precise and conformal dose distributions within target volumes [18]. This achievement owes its realization to the advent of the multileaf collimator (MLC) [5].

Radiation therapy is now a reliable treatment for oncology [14]. Despite this consensus, the way to deliver radiotherapy for its best result remains very dependent upon doctors. Moreover, there appears to be a large variability across physicians and centres, but in terms of 3D structures contouring and irradiation, constrains priorities [3].

To achieve the best treatment, doctors must solve a complex inverse mathematical optimization problem with multiple trade-offs [10] [15]. A lack of standardized prioritization of constraints makes the optimization a real challenge. The standard procedure nowadays is to guide computer optimization manually: dosimetrists manually update the settings of an optimizing software so-called Treatment Planning System (TPS) [1].

There have been many tries to create a metric that quantifies the quality of a treatment plan, such as Normal Tissue Complication Probabilities (NTCP), target coverage, conformity index, and heterogeneity index, among others/to name a few [8] [7]. However, they have yet to satisfy all radio-oncologists, and the only reliable way to assess a doctor's plan is to evaluate the dose-volume histograms (DVHs) themselves.

As a result, Pareto surface exploration is unsuitable due to the lack of impartial quantitative measurement for a particular plan [6]. Other meta-optimization techniques are similarly bounded for the same reason [16] [17]. An extra challenge to attend for those is the fact that not all cases have the same "difficulty." Hence, for an "easy" case, doctors will require an excellent dose (in terms of the metrics mentioned above), while they can be more permissive for "harder" cases. This makes the acceptability of a plan hard to define in general.

Reinforcement learning (RL) is a machine learning paradigm that trains agents to make sequential decisions in dynamic environments [2]. Through trial and error guided by rewards or penalties, agents learn to optimize their actions to achieve long-term objectives. The decisions taken by dosimetrists when optimizing treatment can be formalized as a RL problem. Moreover, dosimetrists can guide the TPS towards an acceptable plan but usually struggle to explain their decision while interacting with the TPS. The difficulty in explaining why certain decisions are taken suggests using deep RL over expert-based methods. This setup is similar to image recognition, where one can say a picture represents a car or a boat but struggles to explain why.

We sought to leverage deep learning to learn the actions a dosimetrist takes when optimizing a dose using a treatment planning system. The study's primary hypothesis was that all the information needed to decide what weights should be changed in the objective function used by the optimizer relies on the Dose Volume Histograms (DVHs). This assumption is supported by the fact that dosimetrists almost solely use those DVHs plots. We trained an agent that takes

as an input the DVHs of the current optimized dose, and predicts the evaluation of possible weights changes.

We allowed our-self to use the dose distributions of previously treated patients to train our model. However, we consider that access to the exact actions taken by human dosimetrists on the TPS is unavailable (as clinics do not usually store this data; only the final plan is held). This data availability suggests the use of RL.

2 Materials and Methods

We introduce a new paradigm for reward-based dosimetrist RL agents. This new reward system aims to mimic human-optimized doses better.

2.1 Reinforcement Learning Reward




Fig. 1. Classical reinforcement learning reward for automatic dosimetry.

In classical RL, we want $V(S_t) = R_t + \gamma V(S_{t+1})$ (so the update is $V(S_t) \leftarrow (1 - \alpha)V(S_t) + \alpha \left[R_{t+1} + \gamma V(S_{t+1})\right]$). In the context of dose optimization, the reward R_t is defined as $R_t = \mathcal{E}(S_{t+1}) - \mathcal{E}(S_t)$. Where \mathcal{E} is a function that evaluates the quality of a state (such that higher is better; if lower is better, then swap s_t and S_{t+1}).

The evaluation \mathcal{E} can be one or a mixture of the metrics mentioned in the introduction (Section 1) [12] [13] [9]. This setup may leverage knowledge about which actions to perform instead of guessing randomly as a meta-optimizer would do. We can hope to gain some computation time.

However, this technique does not use past plans; it only needs the optimizer inputs (CT, structures contours). We propose using the availability of past treatment plans to catch better the complexity of decisions made by dosimetrists and better match their expectations of a fully automatic treatment planning system.

As developed in previous work, we can derive a distance between dose plans [11]. If we consider the clinical dose of past cases (used for training) as the best achievable one, we can evaluate a dose plan by computing its distance from the clinical dose plan.

Let D_t be the dose associated with S_t , and D_C the clinical dose. We then define $\mathcal{E}(S_t) = \mathcal{D}(D_t, D_C)$. Since in that case, lower is better, we will define the reward as

$$R_t = \mathcal{E}(S_t) - \mathcal{E}(S_{t+1}) = \mathcal{D}(D_t, D_C) - \mathcal{D}(D_{t+1}, D_C).$$

This reward can be interpreted as the "distance gained to the clinical dose".

2.2 Architecture

We use a dense neural network, taking the DVHs and the current normalized weight values as inputs. It outputs the Q(s,a) Value for each possible action a. Dense layers are very prone to overfitting. In order to force the network to actually predict the following evaluation for each possible action, without overfitting, we incorporated a bottleneck in the network [ref architecture figure]. Compressing the information stops the network from overfitting. Networks with such architecture show significantly better results on validation.

2.3 Avoiding Off-Distribution

We generated a training set of over 125k actions (this took five days on an NVIDIA GeForce GTX 1080). Despite this relatively large dataset, we have not explored exhaustively the state-actions space, and the network still gets off distribution. This can easily be spotted when the predicted distance is negative; we choose to ignore those predictions. In fact, we ignore all outlier predictions. The justification is that our set of actions is limited, no action will suddenly drastically improve the plan. It is the combination of several sequential actions that allows good plan optimization. Therefore, while testing, we choose the action with the best prediction, while passing the outlier test just mentioned.

3 Results

Figure 3 show how the distance between our RL agent's perform over five steps on 30 test patients (unseen during the training). A lower distance is interpreted as a better dose (as it is closer to the best dose; the clinical one).

3.1 Quantitative Results

The network was able to converge on the training data, and validation showed some minor overfitting. For testing, we generated 30 brand new cases that we again manually optimized. We then used the RL model to perform the optimization of those 30 unseen cases. On average, our model was able to reduce the dose




Fig. 2. Neural network architecture and Loss evolution while training.




Fig. 3. Average distance between RL agent's dose and clinical dose.

distance with manually optimized dose by a factor of 2.5 (from 2.2 at iteration 0 to 0.91 at iteration 4), as shown in the table 3.1 (* means lower is better; † means higher is better).

Agent \ Metric	Mean Final Distance*	Homogeneity Score [†]	Conformity Score [†]
RL Distance Score	0.91	2.31	0.18
RL Homogeneity Score	2.31	5.17	0.5
RL Conformity Score	1.87	4.99	0.34
Meta-optimization	1.81	3.78	0.36

3.2 Qualitative Results

Figure 4 is the detail of the DVHs at each of the five steps of an optimization on one of the test patient (unseen by the agent during the training). Our model was able to drastically reduce the dose distance with manually optimized dose. Visual inspection of the DVHs plot can show that the dose optimized by the RL agent is very close to the clinical (manually fine-tuned) one.

4 Discussion

Our study demonstrates the potential of deep reinforcement learning (RL) for automating radiotherapy treatment plan optimization. A key strength of our approach is its ability to learn from past treatment plans, capturing the complex decision-making processes of human dosimetrists. This data-driven approach avoids the limitations of pre-defined metrics, which may not fully capture the nuances of optimal treatment planning.

However, our study also has limitations. The agent's performance relies on the quality and quantity of available training data. Cases with limited historical




Fig. 4. RL Agent DVHs after each action taken on a test (unseen) patient. Solid lines are the agent's dose DVHs; dotted ones are the reference dose DVHs (manually finetuned).

data or complex anatomical features may require additional strategies. Moreover, while the agent achieves promising results in terms of dose distance reduction, it is not guaranteed that the dose will be clinically acceptable. Finally, while this study demonstrates the promise of our RL approach in a controlled setting, extending it to real-world radiotherapy planning necessitates addressing additional complexities and constraints.

Several avenues exist for further research. Firstly, we plan to investigate strategies for incorporating additional information, such as patient characteristics and anatomical complexities, into the training process. Secondly, we aim to explore techniques for improving the interpretability of the agent's decision-making process, allowing for better understanding and potential clinical validation.

Appendix

As this is very new and ongoing research, we generated synthetic phantom patients and associated trustable clinical doses. In future work, we hope to apply this technique to real cases.

Synthetic phantom patients

We generated 130 patients with oval axial section bodies. We set the body density to water density. We then added an ellipsoid PTV within the body, with a slightly different density (following $\mathcal{N}(1,0.05)$). Likewise, we generate five organs gravitating around the PTV, aligned on the axial section.

Clinical dose

After generating the patient's CT and structures, we needed to create a reference dose that our agent should mimic. We manually set weights and performed a standard optimization. The dose prescription is a standard 80Gy on PTV, and is the same across all patients.

Optimization

We optimize the plan using the LBFGS optimizer (shown to be the most appropriate in [4]). For each DVH constraint (e.g. for PTV, $D_{95} > 80 \ Gy$), we used a linear penalization of the overdose.




Fig. 5. Example of a (generated) patient:
Left: Main axial slice (center of the PTV) CT.
Right: Main axial slice (center of the PTV) of the clinical dose.
Bottom: Associated clinical dose DVH.

References

- 1. Treatment Planning System Basics | Oncology Medical Physics, https://oncologymedicalphysics.com/introduction-to-treatment-planning-systems/
- 2. Brooks, R.: What is reinforcement learning? (Dec 2021), https://online.york.ac.uk/what-is-reinforcement-learning/
- 3. Das, I.J., Compton, J.J., Bajaj, A., Johnstone, P.A.: Intra- and inter-physician variability in target volume delineation in radiation therapy. Journal of Radiation Research p. rrab080 (Sep 2021). https://doi.org/10.1093/jrr/rrab080, https://academic.oup.com/jrr/advance-article/doi/10.1093/jrr/rrab080/6367625
- 4. Dubois, P.: Radiotherapy Dosimetry: A Review on Open-Source Optimizer (May 2023), http://arxiv.org/abs/2305.18014, arXiv:2305.18014 [cs, eess]
- Galvin, J.M., Smith, A.R., Lally, B.: Characterization of a multileaf collimator system. International Journal of Radiation Oncology*Biology*Physics 25(2), 181–192 (Jan 1993). https://doi.org/10.1016/0360-3016(93)90339-W, https://linkinghub.elsevier.com/retrieve/pii/036030169390339W
- Huang, C., Yang, Y., Panjwani, N., Boyd, S., Xing, L.: Pareto Optimal Projection Search (POPS): Automated Radiation Therapy Treatment Planning by Direct Search of the Pareto Surface. IEEE Transactions on Biomedical Engineering 68(10), 2907–2917 (Oct 2021). https://doi.org/10.1109/TBME.2021.3055822, https://ieeexplore.ieee.org/document/9343695/
- 7. Li, X., Ge, Y., Wu, Q., Wang, C., Sheng, Y., Wang, W., Stephens, H., Yin, F.F., Wu, Q.J.: Input feature design and its impact on the performance of deep learning models for predicting fluence maps in intensity-modulated radiation therapy. Physics in Medicine & Biology 67(21), 215009 (Nov 2022). https://doi.org/10.1088/1361-6560/ac9882, https://iopscience.iop.org/article/10.1088/1361-6560/ac9882
- 8. Lyman, J.T.: Normal tissue complication probabilities: Variable dose per fraction. International Journal of Radiation Oncology*Biology*Physics 22(2), 247–250 (Jan 1992). https://doi.org/10.1016/0360-3016(92)90040-O, https://linkinghub.elsevier.com/retrieve/pii/036030169290040O
- Moreau, G., François-Lavet, V., Desbordes, P., Macq, B.: Reinforcement Learning for Radiotherapy Dose Fractioning Automation. Biomedicines 9(2), 214 (Feb 2021). https://doi.org/10.3390/biomedicines9020214, https://www.mdpi.com/2227-9059/9/2/214
- 10. Oelfke, U., Bortfeld, T.: Inverse planning for photon proton beams. Medical Dosimetry **26**(2), 113 https://doi.org/10.1016/S0958-3947(01)00057-7. 124 (Jun 2001). https://linkinghub.elsevier.com/retrieve/pii/S0958394701000577
- P. Dubois, N. Paragios, P.-H. Cournède, G. Temiz, R. Marini-Silva, N. Bus, P. Fenoglietto: A Novel Framework for Multi-Objective Optimization and Robust Plan Selection Using Graph Theory. Glasgow (UK) (2024)
- 12. Shen, C., Chen, L., Jia, X.: A hierarchical deep reinforcement learning framework for intelligent automatic treatment planning of prostate cancer intensity modulated radiation therapy. Physics in Medicine & Biology 66(13), 134002 (Jul 2021). https://doi.org/10.1088/1361-6560/ac09a2, https://iopscience.iop.org/article/10.1088/1361-6560/ac09a2
- 13. Shen, C., Gonzalez, Y., Klages, P., Qin, N., Jung, H., Chen, L., Nguyen, D., Jiang, S.B., Jia, X.: Intelligent Inverse Treatment Planning via Deep Reinforcement Learning, a Proof-of-Principle Study in High

- Dose-rate Brachytherapy for Cervical Cancer. Physics in Medicine & Biology **64**(11), 115013 (May 2019). https://doi.org/10.1088/1361-6560/ab18bf, http://arxiv.org/abs/1811.10102, arXiv:1811.10102 [physics]
- Valentini, V., Cellini, F., Minsky, B.D., Mattiucci, G.C., Balducci, M., D'Agostino, G., D'Angelo, E., Dinapoli, N., Nicolotti, N., Valentini, C., La Torre, G.: Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. Radiotherapy and Oncology 92(2), 176–183 (Aug 2009). https://doi.org/10.1016/j.radonc.2009.06.014, https://linkinghub.elsevier.com/retrieve/pii/S0167814009003247
- 15. Webb, S.: The physical basis of IMRT and inverse planning. The British Journal of Radiology **76**(910), 678–689 (Oct 2003). https://doi.org/10.1259/bjr/65676879, https://academic.oup.com/bjr/article/76/910/678-689/7470601
- Wu, X., Zhu, Y.: An optimization method for importance factors and beam weights based on genetic algorithms for radiotherapy treatment planning. Physics in Medicine and Biology 46(4), 1085–1099 (Apr 2001). https://doi.org/10.1088/0031-9155/46/4/313, https://iopscience.iop.org/article/10.1088/0031-9155/46/4/313
- 17. Xing, L., Li, J.G., Donaldson, S., Le, Q.T., Boyer, A.L.: Optimization of importance factors in inverse planning. Physics in Medicine and Biology 44(10), 2525–2536 (Oct 1999). https://doi.org/10.1088/0031-9155/44/10/311, https://iopscience.iop.org/article/10.1088/0031-9155/44/10/311
- 18. Xu, D., Li, G., Li, H., Jia, F.: Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis. Medicine 96(31), e7685 (Aug 2017). https://doi.org/10.1097/MD.00000000000007685, https://journals.lww.com/00005792-201708040-00033